Neovacs SA
ALNEV
Company Profile
Business description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Contact
3-5, Impasse Reille
Paris75014
FRAT: +33 153109300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,631.50 | 42.70 | 0.50% |
| CAC 40 | 7,826.79 | 1.34 | -0.02% |
| DAX 40 | 24,226.49 | 198.84 | 0.83% |
| Dow JONES (US) | 42,251.51 | 648.44 | 1.56% |
| FTSE 100 | 8,778.05 | 60.08 | 0.69% |
| HKSE | 23,381.99 | 99.66 | 0.43% |
| NASDAQ | 19,174.57 | 437.36 | 2.33% |
| Nikkei 225 | 37,724.11 | 192.58 | 0.51% |
| NZX 50 Index | 12,582.33 | 35.11 | 0.28% |
| S&P 500 | 5,912.68 | 109.86 | 1.89% |
| S&P/ASX 200 | 8,407.60 | 46.60 | 0.56% |
| SSE Composite Index | 3,340.69 | 6.15 | -0.18% |